Objective: Evaluate safety/tolerability of ABBV-951 delivered via continuous subcutaneous infusion(CSCI) in Parkinson's disease(PD) patients.Background: ABBV-951 is a new soluble formulation of carbidopa and levodopa prodrugs, delivered as a CSCI via an external pump, being developed for the ...
ABBV receives CRL for ABBV-951 NDA for the treatment of motor fluctuations in adults with advanced Parkinson's disease.$艾伯维公司(ABBV)$cns 全部讨论 第二次收到了CRL,皮下注射加个遥控器一样的pump还是天坑的神经系统类适应症 不和CMO工厂把这种药械结合的产品cmc过程完善提供准资料就是这个结果,坐等第...